Current advances in research of semaphorin 3A:a potential target for the treatment of nospecific low back pain.
10.12200/j.issn.1003-0034.2021.06.021
- Author:
Long XIN
1
;
Wei-Xing XU
1
;
Jian WANG
1
;
Hong-Pu SONG
1
;
Jian LIU
1
;
Jin WANG
1
;
Shun-Wu FAN
1
;
Yang YANG
1
Author Information
1. Department of Orthopaedics, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang, China.
- Publication Type:Journal Article
- Keywords:
Intervertebral disc degeneration;
Low back pain;
Sema3A
- MeSH:
Endothelial Cells;
Humans;
Low Back Pain;
Neuropilin-1;
Semaphorin-3A;
Vascular Endothelial Growth Factor A
- From:
China Journal of Orthopaedics and Traumatology
2021;34(6):589-592
- CountryChina
- Language:Chinese
-
Abstract:
Nonspecific low back pain is closely associated with afferent nerve ingrowth into degenerated IVDs and increasing the inflammatory response. Members of the class 3 semaphorins signal their response through two prominent receptors; the NRP (Neuropilin-1) and the Plexin A. Sema3A (Semaphorin3A) is primarily known for their role in modulating neuronal survival as well as neurite outgrowth and guidance via regulation of Sema3A-NRP-1-plexinA signal pathway. Also, sema3A is shown to be conductive to innervate the inner painful degenerated IVDs (Intervertebral discs). Furthermore, sema3A is thought to act as a barrier to endothelial cells survival and migration on vascular endothelial growth factor (VEGF) and inhibition of KLF5-induced (Krüppel-like factor 5) inflammatory mediators within degenerated IVDs. Therefore, Sema3A produce a new perspective of dual-action therapeutic agent for attenuating the regulator of innervation and angiogenesis into degenerated IVDs and inhibition of KLF5-induced inflammation.
